CA2322549A1 - Produits medicaux obtenus a partir du chanvre en utilisant des profiles de cannabinoides comme indicateurs d'efficacite - Google Patents

Produits medicaux obtenus a partir du chanvre en utilisant des profiles de cannabinoides comme indicateurs d'efficacite Download PDF

Info

Publication number
CA2322549A1
CA2322549A1 CA002322549A CA2322549A CA2322549A1 CA 2322549 A1 CA2322549 A1 CA 2322549A1 CA 002322549 A CA002322549 A CA 002322549A CA 2322549 A CA2322549 A CA 2322549A CA 2322549 A1 CA2322549 A1 CA 2322549A1
Authority
CA
Canada
Prior art keywords
plant
cannabis
powder
cannabinoid
profile
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002322549A
Other languages
English (en)
Inventor
A. Paul Hornby
Martin D. Sutherland
Pavel U. Dimotoff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CA002322549A priority Critical patent/CA2322549A1/fr
Publication of CA2322549A1 publication Critical patent/CA2322549A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01H—NEW PLANTS OR NON-TRANSGENIC PROCESSES FOR OBTAINING THEM; PLANT REPRODUCTION BY TISSUE CULTURE TECHNIQUES
    • A01H3/00—Processes for modifying phenotypes, e.g. symbiosis with bacteria
    • A01H3/02—Processes for modifying phenotypes, e.g. symbiosis with bacteria by controlling duration, wavelength, intensity, or periodicity of illumination
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01H—NEW PLANTS OR NON-TRANSGENIC PROCESSES FOR OBTAINING THEM; PLANT REPRODUCTION BY TISSUE CULTURE TECHNIQUES
    • A01H3/00—Processes for modifying phenotypes, e.g. symbiosis with bacteria
    • A01H3/04—Processes for modifying phenotypes, e.g. symbiosis with bacteria by treatment with chemicals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01H—NEW PLANTS OR NON-TRANSGENIC PROCESSES FOR OBTAINING THEM; PLANT REPRODUCTION BY TISSUE CULTURE TECHNIQUES
    • A01H5/00—Angiosperms, i.e. flowering plants, characterised by their plant parts; Angiosperms characterised otherwise than by their botanic taxonomy
    • A01H5/12—Leaves
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01H—NEW PLANTS OR NON-TRANSGENIC PROCESSES FOR OBTAINING THEM; PLANT REPRODUCTION BY TISSUE CULTURE TECHNIQUES
    • A01H6/00—Angiosperms, i.e. flowering plants, characterised by their botanic taxonomy
    • A01H6/28—Cannabaceae, e.g. cannabis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Botany (AREA)
  • Developmental Biology & Embryology (AREA)
  • Environmental Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Physiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medical Informatics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002322549A 2000-09-27 2000-09-27 Produits medicaux obtenus a partir du chanvre en utilisant des profiles de cannabinoides comme indicateurs d'efficacite Abandoned CA2322549A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA002322549A CA2322549A1 (fr) 2000-09-27 2000-09-27 Produits medicaux obtenus a partir du chanvre en utilisant des profiles de cannabinoides comme indicateurs d'efficacite

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA002322549A CA2322549A1 (fr) 2000-09-27 2000-09-27 Produits medicaux obtenus a partir du chanvre en utilisant des profiles de cannabinoides comme indicateurs d'efficacite

Publications (1)

Publication Number Publication Date
CA2322549A1 true CA2322549A1 (fr) 2002-03-27

Family

ID=4167327

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002322549A Abandoned CA2322549A1 (fr) 2000-09-27 2000-09-27 Produits medicaux obtenus a partir du chanvre en utilisant des profiles de cannabinoides comme indicateurs d'efficacite

Country Status (1)

Country Link
CA (1) CA2322549A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005000830A1 (fr) * 2003-06-24 2005-01-06 Gw Pharma Limited Compositions pharmaceutiques contenant des composes de type cannabichromene
US7320805B2 (en) * 2003-10-01 2008-01-22 Institut National De La Sante Et De La Recherche Medicale CB2 receptors blocks accumulation of human hepatic myofibroblasts: a novel artifibrogenic pathway in the liver
US10004684B2 (en) 2001-02-14 2018-06-26 Gw Pharma Limited Pharmaceutical formulations

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10004684B2 (en) 2001-02-14 2018-06-26 Gw Pharma Limited Pharmaceutical formulations
WO2005000830A1 (fr) * 2003-06-24 2005-01-06 Gw Pharma Limited Compositions pharmaceutiques contenant des composes de type cannabichromene
US8470874B2 (en) 2003-06-24 2013-06-25 Gw Pharma Limited Pharmaceutical compositions comprising cannabichromene type compounds
US7320805B2 (en) * 2003-10-01 2008-01-22 Institut National De La Sante Et De La Recherche Medicale CB2 receptors blocks accumulation of human hepatic myofibroblasts: a novel artifibrogenic pathway in the liver

Similar Documents

Publication Publication Date Title
US10207199B2 (en) Methods of purifying cannabinoids using liquid:liquid chromatography
CA3012514C (fr) Production et utilisation de cannabis de specialite ayant un profil de genotype bd/bt et un terpene a dominance de terpinolene
Valdes et al. Coleus barbatus (C. forskohlii)(Lamiaceae) and the potential new drug forskolin (Coleonol)
US20160214920A1 (en) Methods of Purifying Cannabinoids, Compositions and Kits Thereof
Janatová et al. Yield and cannabinoids contents in different cannabis (Cannabis sativa L.) genotypes for medical use
AU674710B2 (en) Novel extracts of cucurbita sp., process for their preparation and use in medicaments and in cosmetics
Ruan et al. Novel 2H-chromen-2-one derivatives of resveratrol: design, synthesis, modeling and use as human monoamine oxidase inhibitors
CA2322549A1 (fr) Produits medicaux obtenus a partir du chanvre en utilisant des profiles de cannabinoides comme indicateurs d'efficacite
Thomas et al. Artemisinin—an innovative cornerstone for anti-malaria therapy
Tucker Floral development and homeosis in Saraca (Leguminosae: Caesalpinioideae: Detarieae)
CN105054284B (zh) 清爽典雅香型的电子烟雾化液及其制备方法
JP4044274B2 (ja) 微生物性リパーゼ阻害剤、及びこれを含有するニキビ用皮膚外用剤並びにフケ用皮膚外用剤
Ibrahim et al. Antioxidant activity, phenol and flavonoid contents of plant and callus cultures of Plectranthus barbatus andrews
DE4303823C2 (de) Verwendung eines Extraktes aus Blüten von Salvia officinalis bei der Bekämpfung von Durchblutungsstörungen
De Langhe et al. Effect of hormones on nucleolar growth and vacuolation in elongating cotton fibers
Svajdlenka et al. Essential oil composition of Thuja occidentalis L. Samples from Slovakia
Mariswamy et al. GC-MS studies on methanolic extracts of Aerva lanata L
Carvalho et al. Pharmaceutical Evaluation of Medical Cannabis Extracts Prepared by Artisanal and Laboratory Techniques
Kaffash et al. Comparing essential oil composition of cultivated and wild samples of Achillea biebersteinii Afan. in Kurdistan Province.
Scott Medicinal and aromatic plants
BOKOV MUSCARI ARMENIACUM LEICHTLIN (GRAPE HYACINTH): PHYTOCHEMISTRY AND BIOLOGICAL ACTIVITIES REVIEW
US20220386548A1 (en) Cannabis plant named 'hba-2-x'
Chagonda et al. Essential oils of cultivated Heteropyxis natalensis (Harv.) and cultivated Heteromorpha trifoliata (Wendl.) Eckl. & Zey. from Zimbabwe
williams Ranking anti m icrobial activity
Kotik et al. Adventitious bud formation and plantlet regeneration of Achyrocline satureoides-a multipurpose medicinal plant

Legal Events

Date Code Title Description
FZDE Discontinued